Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,007
  • Shares Outstanding, K 84,614
  • Annual Sales, $ 1,410 K
  • Annual Income, $ -62,420 K
  • EBIT $ -67 M
  • EBITDA $ -67 M
  • 60-Month Beta -0.07
  • Price/Sales 13.04
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.95
  • Most Recent Earnings $-0.22 on 02/17/26
  • Next Earnings Date 05/21/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 323.12% (+41.91%)
  • Historical Volatility 158.51%
  • IV Percentile 78%
  • IV Rank 32.69%
  • IV High 818.65% on 02/27/26
  • IV Low 82.45% on 02/06/26
  • Expected Move (DTE 17) 0.4505 (218.90%)
  • Put/Call Vol Ratio 14.75
  • Today's Volume 126
  • Volume Avg (30-Day) 154
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 15,076
  • Open Int (30-Day) 13,860
  • Expected Range 0.0000 to 0.6563

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 3
  • High Estimate $-0.07
  • Low Estimate $-0.15
  • Prior Year $-0.40
  • Growth Rate Est. (year over year) +70.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1611 +27.75%
on 03/24/26
0.4610 -55.36%
on 03/10/26
-0.2149 (-51.08%)
since 02/27/26
3-Month
0.1611 +27.75%
on 03/24/26
2.0300 -89.86%
on 12/30/25
-1.6142 (-88.69%)
since 12/26/25
52-Week
0.1611 +27.75%
on 03/24/26
3.3900 -93.93%
on 08/26/25
-1.1142 (-84.41%)
since 03/28/25

Most Recent Stories

More News
Outlook Therapeutics Announces Closing of $5.0 Million Public Offering

ISELIN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering

ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Proposed Public Offering

ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces New $18.4 Million Non-Convertible Note Financing and Amendment to Existing Convertible Note

ISELIN, N.J., March 16, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Update Following Type A Meeting with FDA Regarding ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Expands European Footprint with Exclusive Commercial Distribution Agreement with Mediconsult AG for LYTENAVA™ (bevacizumab gamma) in Switzerland

Veteran ophthalmology leader with 35+ years of market expertise selected as exclusive Switzerland partner Mediconsult to seek Marketing Authorization and lead commercialization activities for LYTENAVA™...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update

Continued expansion of LYTENAVA™ (bevacizumab gamma) in Europe underway, including commercial launch in Austria in January 2026 Additional European launches expected in 2026 Type A meeting...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter

ISELIN, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

ISELIN, N.J., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of...

OTLK : 0.2058 (+2.39%)
OTLKW : 0.03 (-1.96%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 0.2343
2nd Resistance Point 0.2229
1st Resistance Point 0.2120
Last Price 0.2058
1st Support Level 0.1897
2nd Support Level 0.1783
3rd Support Level 0.1674

See More

52-Week High 3.3900
Fibonacci 61.8% 2.1566
Fibonacci 50% 1.7756
Fibonacci 38.2% 1.3945
Last Price 0.2058
52-Week Low 0.1611

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.